Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

The researchers show that ephrin-B2 regulates the proper spatial activation of VEGFR-2 endocytosis and signaling ... used in people suffering from cancer. Blocking ephrin-B2 signaling in tumors ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

As an oral inhibitor of VEGF receptor (VEGFR)-1, -2 and -3, the therapy functions by blocking the formation of new blood vessels in tumours, decelerating cancer growth. Takeda Canada operates as ...

The VEGF/VEGFR-2 pathways are central to angiogenesis ... and pembrolizumab to treat rGBM and triple-negative breast cancer (TNBC) and will further investigate the safety of this combination.

Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.

and for adult and pediatric patients aged 12 years and above with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and ...